fbpx
 List – 55 Drug Patents that are Expiring in 2026

List – 55 Drug Patents that are Expiring in 2026

2

Avycaz
Ceftazidime / Avibactam

PatentsExpiration Date
US7112592January 7, 2026
US8471025August 12, 2031
US9284314June 15, 2032
US9695122June 15, 2032
US8969566June 15, 2032

Dosage:  Intravenous infusion
Company: Allergan
Ingredients: AVIBACTAM SODIUM; CEFTAZIDIME
Treatment: Intra-abdominal Infections, Urinary Tract Infections, and Pneumonia

Tavalisse
Fostamatinib

PatentsExpiration Date
US8211889January 19, 2026
US7538108March 28, 2026
US7989448June 12, 2026
US8163902June 17, 2026
US7449458September 4, 2026

Dosage:  Oral
Company: Rigel Pharmaceuticals
Ingredients: FOSTAMATINIB DISODIUM
Treatment: Chronic Immune Thrombocytopenia

Bridion
Sugammadex

PatentsExpiration Date
USRE44733January 27, 2026

Dosage: Intravenous
Company: Merck & Co., Inc
Ingredients: SUGAMMADEX SODIUM
Treatment: Reversal of Neuromuscular Blockade Induced by Rocuronium

Briviact
Brivaracetam

PatentsExpiration Date
US6911461February 21, 2026

Dosage: Oral, Intravenous
Company: UCB Group
Ingredients: BRIVARACETAM
Treatment: Partial-onset Seizures in People 1 month of age and older

Procoralan
Ivabradine

PatentsExpiration Date
US7361650February 22, 2026
US7361649February 22, 2026
US7879842February 22, 2026
US7867996December 12, 2026

Dosage: Oral
Company: Servier
Ingredients: IVABRADINE
Treatment: Symptomatic Management of Stable Heart-related Chest Pain and Heart Failure

Pradaxa
Dabigatran

PatentsExpiration Date
US7932273March 7, 2026

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: DABIGATRAN ETEXILATE MESYLATE
Treatment: Blood clots, Stroke

Ozempic
Semaglutide

PatentsExpiration Date
US8536122March 20, 2026
US8129343December 5, 2031

Dosage: Oral, Subcutaneous
Company: Novo Nordisk
Ingredients: SEMAGLUTIDE
Treatment: Type 2 Diabetes

Byetta
Exenatide

PatentsExpiration Date
US6515117April 4, 2026

Dosage: Subcutaneous
Company: AstraZeneca
Ingredients: EXENATIDE SYNTHETIC
Treatment: Type 2 Diabetes

Rexulti
Brexpiprazole

PatentsExpiration Date
US7888362April 12, 2026
USRE48059December 23, 2028

Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: BREXPIPRAZOLE
Treatment: Schizophrenia, Major Depressive Disorder

Aveed
Nebido

PatentsExpiration Date
US11179402April 14, 2026
US10617696April 12, 2030

Dosage: Oral, Intramuscular injection
Company: Endo Pharmaceuticals
Ingredients: TESTOSTERONE UNDECANOATE
Treatment: Low Testosterone Levels in Men

Aptiom
Eslicarbazepine acetate

PatentsExpiration Date
US9206135April 21, 2026

Dosage: Oral
Company: Sumitomo Pharma Co
Ingredients: ESLICARBAZEPINE ACETATE
Treatment: Partial-onset Seizures Epilepsy

Vocabria
Cabotegravir

PatentsExpiration Date
US8410103April 28, 2026
US10927129April 28, 2026

Dosage: Oral, Intramuscular Injection
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR
Treatment: HIV/AIDS

Jevtana
Cabazitaxel

PatentsExpiration Date
US7241907June 10, 2026

Dosage: Intravenous
Company: Sanofi-aventis
Ingredients: CABAZITAXEL
Treatment: Metastatic Castration-resistant Prostate Cancer

Voltaren
Diclofenac

PatentsExpiration Date
US8097651June 16, 2026
US7759394June 16, 2026

Dosage: Oral, Rectal, Intramuscular, Intravenous, Topical
Company: GSK
Ingredients: DICLOFENAC POTASSIUM
Treatment: Inflammatory Diseases such as Gout

Trintellix
Vortioxetine

PatentsExpiration Date
US7144884June 17, 2026
US8722684June 30, 2031

Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: VORTIOXETINE HYDROBROMIDE
Treatment: Major Depressive Disorder

Zelboraf
Vemurafenib

PatentsExpiration Date
US8143271June 21, 2026
US7504509October 22, 2026
US7863288June 20, 2029
US8741920July 27, 2030

Dosage: Oral
Company: Genentech
Ingredients: VEMURAFENIB
Treatment: Late-stage Melanoma

Rhopressa
Netarsudil

PatentsExpiration Date
US8450344July 11, 2026
US9096569July 11, 2026
US10174017January 27, 2030
US10654844January 27, 2030
US8394826November 10, 2030
US9931336March 14, 2034
US10588901March 14, 2034
US9415043March 14, 2034

Dosage: Eye drops, Topical
Company: Aerie Pharmaceuticals
Ingredients: NETARSUDIL MESYLATE
Treatment: Glaucoma

Gilotrif
Afatinib

PatentsExpiration Date
USRE43431July 13, 2026
US8426586April 10, 2030

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: AFATINIB DIMALEATE
Treatment: Non-small Cell Lung Carcinoma

Beleodaq
Belinostat

PatentsExpiration Date
US6888027August 10, 2026

Dosage: Intravenous
Company: Acrotech Biopharma LLC
Ingredients: BELINOSTAT
Treatment: Hematological Malignancies and Solid Tumors

Cometriq
Cabozantinib

PatentsExpiration Date
US7579473August 14, 2026
US11091439January 15, 2030
US8877776October 8, 2030

Dosage: Oral
Company: Exelixis, Inc
Ingredients: CABOZANTINIB S-MALATE
Treatment: Medullary Thyroid Cancer, Renal Cell Carcinoma, and Hepatocellular Carcinoma

Isturisa
Osilodrostat

PatentsExpiration Date
US8835646August 23, 2026
US8314097March 27, 2029
US9434754January 13, 2031

Dosage: Oral
Company: Recordati Rare Diseases Inc
Ingredients: OSILODROSTAT PHOSPHATE
Treatment: Cushing’s Disease

Samsca
Tolvaptan

PatentsExpiration Date
US8501730September 1, 2026

Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: TOLVAPTAN
Treatment: Hyponatremia

Sprycel
Dasatinib

PatentsExpiration Date
US7491725September 28, 2026

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DASATINIB
Treatment: Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia

Aklief
Trifarotene

PatentsExpiration Date
US7807708October 1, 2026

Dosage: Topical
Company: Galderma Laboratories
Ingredients: TRIFAROTENE
Treatment: Acne Vulgaris

Symproic
Naldemedine

PatentsExpiration Date
USRE46375October 5, 2026
USRE46365January 11, 2028
US9108975November 11, 2031
US10952968May 13, 2033

Dosage: Oral
Company: Shionogi & Co
Ingredients: NALDEMEDINE TOSYLATE
Treatment: Opioid-induced Constipation

Saphris
Asenapine

PatentsExpiration Date
US7741358October 6, 2026
US8022228October 6, 2026

Dosage: Sublingual
Company: Merck Sharp & Dohme
Ingredients: ASENAPINE MALEATE
Treatment: Schizophrenia

Uptravi
Selexipag

PatentsExpiration Date
US7205302October 31, 2026
US8791122August 1, 2030

Dosage: Oral, intravenous
Company: Actelion Pharmaceuticals
Ingredients: SELEXIPAG
Treatment: Pulmonary Arterial Hypertension

Bevyxxa
Betrixaban

PatentsExpiration Date
US7598276November 8, 2026

Dosage: Oral
Company: Portola Pharmaceuticals, Inc
Ingredients: BETRIXABAN
Treatment: Venous Thrombosis

Orkambi
Lumacaftor / Ivacaftor

PatentsExpiration Date
US9216969November 8, 2026
US10597384December 4, 2028
US8507534September 20, 2030

Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR; LUMACAFTOR
Treatment: Cystic Fibrosis

Eliquis
Apixaban

PatentsExpiration Date
US6967208November 21, 2026

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: APIXABAN
Treatment: Blood Clots

Calquence
Acalabrutinib

PatentsExpiration Date
US7459554November 24, 2026
US9290504July 11, 2032
US9796721July 1, 2036

Dosage: Oral
Company: AstraZeneca
Ingredients: ACALABRUTINIB
Treatment: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma

Sirturo
Bedaquiline

PatentsExpiration Date
US7498343December 1, 2026
US8546428March 19, 2029

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: BEDAQUILINE FUMARATE
Treatment: Multi-drug-resistant Tuberculosis

Adempas
Riociguat

PatentsExpiration Date
US7173037December 4, 2026
US10662188February 18, 2034
US11203593February 18, 2034

Dosage: Oral
Company: Bayer
Ingredients: RIOCIGUAT
Treatment: Pulmonary Hypertension

Moxatag
Amoxicillin

PatentsExpiration Date
US8778924December 8, 2026

Dosage: Oral, intravenous
Company: Pragma Pharmaceuticals
Ingredients: AMOXICILLIN
Treatment: Bacterial Infections

Inrebic
Fedratinib

PatentsExpiration Date
US7528143December 16, 2026
US7825246December 16, 2026

Dosage: Oral
Company: Impact Biomedicines
Ingredients: FEDRATINIB HYDROCHLORIDE
Treatment: Myeloproliferative

Imbruvica
Ibrutinib

PatentsExpiration Date
US8697711December 28, 2026
US9181257December 28, 2026
US8957079December 28, 2026
US8735403December 28, 2026
US7514444December 28, 2026
US8008309November 13, 2027
US10125140June 3, 2033
US9725455June 3, 2033
US10106548June 3, 2033
US9296753October 30, 2033

Dosage: Oral
Company: Janssen Biotech
Ingredients: IBRUTINIB
Treatment: Chronic Lymphocytic Leukemia

Kalydeco
Ivacaftor

PatentsExpiration Date
US8754224December 28, 2026
US7495103May 20, 2027

Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR
Treatment: Cystic Fibrosis

Showing 2 comments
  • Prasanna Kumar B
    Reply

    Well information and useful

  • Nguyễn Thoại Cương
    Reply

    Useful and clearly data. Many thanks!

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.